Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CTWondergem, Maurits, MD, PhD; van der Zant, Friso, MD, PhD; Broos, Wouter, MD; Knol, Remco, MD, PhDClinical Nuclear Medicine: July 2019 - Volume 44 - Issue 7 - p 582–584 doi: 10.1097/RLU.0000000000002585 Interesting Images Buy Abstract Author InformationAuthors Article MetricsMetrics Radioisotope-labeled prostate-specific membrane antigen PET/CT is increasingly used for detection of prostate cancer most often in the setting of biochemical recurrence or in primary staging. This report shows increased PSMA expression in lymph node metastases 3 months after initiation of enzalutamide for castration-resistant prostate cancer, whereas lymph node volume and serum prostate-specific antigen decreases over time. This case demonstrates that increasing 18F-DCFPyL uptake after initiation of androgen deprivation therapy should not be confused with disease progression. From the Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. Received for publication December 24, 2018; revision accepted March 2, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Maurits Wondergem, MD, PhD, Noordwest Ziekenhuisgroep Alkmaar, Noord Holland, The Netherlands. E-mail: M.firstname.lastname@example.org. Online date: May 3, 2019 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.